ReviewBiomarkers in medicine2012
Early diagnosis of pancreatic cancer: challenges and new developments.
Review in Biomarkers in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis.Cancer research communications · 2022Pooled it
- A case-control study in Taiwanese cohort and meta-analysis of serum ferritin in pancreatic cancer.Scientific reports · 2021Pooled it
- Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review.BMC cancer · 2021Pooled it
- Pooled it
- Trial
- Peptide-Based Probe Targeting Angiotensin Type‑1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography.Chemical & biomedical imaging · 2026Article
- Radiomics-Driven Machine Learning Models for Diagnosis of Pancreatic Adenocarcinoma.Iranian journal of medical sciences · 2026Article
- Balancing Intrinsic and Extrinsic Factors in CD8Immune network · 2026Review
- CAPG serves as a prognostic biomarker and promotes proliferation and migration in pancreatic ductal adenocarcinoma.PloS one · 2026Article
- Gene expression profiling and predictive modeling of cancer biomarkers using machine learning and IoT-Enabled biosensors.Scientific reports · 2025Article
- Review
- Exploring the prognostic role of cluster of differentiation 47 in patients with advanced pancreatic cancer: a comparative cohort study.Annals of surgical treatment and research · 2025Article
- Extracellular derived-exosomal micrornas in pancreatic cancer: investigating their diagnostic importance and potential targets for the prevention and treatment in pancreatic cancer.Frontiers in oncology · 2025Review
- Pancreatic cancer mortality trend in Montenegro, 1990-2018.Gastroenterology report · 2025Article
- Prediction of 12-month recurrence of pancreatic cancer using machine learning and prognostic factors.BMC medical informatics and decision making · 2024Article
- Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients.International journal of molecular sciences · 2024Article
- Clinical Perspectives on the Histomolecular Features of the Pancreatic Precursor Lesions: A Narrative Review.Middle East journal of digestive diseases · 2024Review
- circ_WASF2 regulates ferroptosis by miR-634/ GPX4 signaling in pancreatic cancer.Discover oncology · 2024Article
- Exploring the Associations of Inflammatory and Oxidative Stress Biomarkers with Pancreatic Diseases: An Observational and Mendelian Randomisation Study.Journal of clinical medicine · 2024Article
- The high FKBP1A expression in WBCs as a potential screening biomarker for pancreatic cancer.Scientific reports · 2024Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pancreatic cancer is a lethal malignancy with its incidence almost equivalent to mortality. The complex pathophysiology, absence of early diagnostic and prognostic markers and unresponsiveness to radiation and chemotherapies are major barriers against successful therapy. Poor performance of therapeutic agents, even in the initial stage of invasive cases, emphasizes the importance of early detection for improved survival. The present review discusses the challenges and advances in biomarkers including serological signatures, circulating tumor cells, autoantibodies, epigenetic markers and miRNAs that are being explored to detect this cancer at early stages. Considering the long time gap between the development of malignant lesions and full-blown primary and metastatic pancreatic cancer, unique opportunities are being contemplated for the development of potential diagnostic and prognostic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.